MEDIFAST INC (MED) Form 10-Q — Oct 26, 2026
Medifast reported Q3 2026 revenue of $72.0 million, down 19.4% year-over-year, with net loss widening to $17.5 million ($1.57 per share) from $2.3 million a year ago. The decline is driven by active earning coaches falling to 10,200 from 19,500, which the company attributes to weak client acquisition amid rapid GLP-1 adoption. Management expects the coach count to keep declining through the end of 2026. The company completed its Catalyst restructuring in the quarter, taking $15.4 million in charges from facility closures and workforce reductions, and continues pivoting from OPTAVIA to the new Trilivy metabolic health brand.
Key figures
- Revenue
- 72048000
- Revenue Yoy
- -19.4%
- Cash Position
- 58372000
- Shares Outstanding
- 11182597
- Gross margin
- 69.5%
- Nine month revenue
- 224476000
- Stockholders equity
- 180277000
- Nine month revenue yoy
- -27.7%
- Total cash investments
- 172534000
- Adjusted net loss q3 2026
- 2100000
- Revenue per coach q3 2026
- 7064
- Active earning coaches q3 2025
- 19500
- Active earning coaches q3 2026
- 10200
- Catalyst restructuring charges
- 15406000
- Average price paid per share aug
- 12.14
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.